Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

Dow Jones

10/28

2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is "somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market." CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com)

(END) Dow Jones Newswires

October 27, 2025 19:37 ET (23:37 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2578706606"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578706606\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578706606?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 07:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578706606","market":"us","top_or_hot":-1,"title":"Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 19:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-28 07:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 19:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL.AU","symbol_name":"CSL LIMITED","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578706606","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578706606","pubTimestamp":1761608220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL.AU":"CSL LIMITED","BK7501":"新冠治疗股","BK4086":"建筑产品","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","CSL":"卡莱尔伙伴","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7508":"医药生物股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7511":"ESG概念","BK7067":"生物科技","ISBC":"投资者银行","BK4211":"区域性银行"},"translate_title":"投资者可能会为CSL推迟Seqirus分拆的决定欢呼——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1.5,"ISBC":1.5},"content_text":"2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 19:37 ET (23:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}